Sanofi SA
PAR:SAN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
84.87
105.76
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Sanofi SA
Sanofi SA
Change in Working Capital
Sanofi SA
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sanofi SA
PAR:SAN
|
Change in Working Capital
-€1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Change in Working Capital
-€174.3m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-34%
|
|
|
Vetoquinol SA
PAR:VETO
|
Change in Working Capital
-€15.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
Virbac SA
PAR:VIRP
|
Change in Working Capital
€6.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boiron SA
PAR:BOI
|
Change in Working Capital
-€8.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
27%
|
CAGR 10-Years
17%
|
|
|
Medincell SA
PAR:MEDCL
|
Change in Working Capital
€3.1m
|
CAGR 3-Years
70%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sanofi SA
Glance View
Sanofi SA is a global healthcare leader, committed to improving health outcomes through the innovation and manufacturing of a diverse range of pharmaceutical products and vaccines. With its roots established over 150 years ago, the company operates a vast network that spans across 100 countries, employing over 100,000 individuals dedicated to advancing medical science. Sanofi's portfolio includes treatments in key therapeutic areas such as diabetes, cardiovascular diseases, and immunology, alongside its robust vaccine division, Sanofi Pasteur. This blend of established products and innovative pipelines, including biopharmaceuticals and gene therapies, positions Sanofi uniquely to meet the evolving healthcare demands of a global population. For investors, Sanofi represents a compelling opportunity due to its strong commitment to research and development, which accounted for approximately 16% of its revenue last year. The company’s strategic initiatives focus on enhancing its product line while also forming strategic alliances and partnerships to foster innovation. Furthermore, Sanofi’s solid financial performance, characterized by consistent revenue growth and healthy dividend payouts, showcases its operational efficiency and reliability. As the healthcare landscape continues to shift, Sanofi's agility in adapting to new challenges, coupled with its focus on science and patient needs, sets it apart as a strong contender in the biopharmaceutical industry, providing investors with a platform for sustainable long-term growth.
See Also
What is Sanofi SA's Change in Working Capital?
Change in Working Capital
-1.1B
EUR
Based on the financial report for Sep 30, 2024, Sanofi SA's Change in Working Capital amounts to -1.1B EUR.
You don't have any saved screeners yet
